While VWF presents an obvious and attractive target to prevent or treat arterial thrombosis, VWF inhibitors have only relatively recently reached the stage of clinical development, and then only in the form of macromolecules such as the monoclonal antibody AJW-20030, the nanobody caplacizumab used in thrombotic thrombocytopenic purpura31–33 and the aptamer ARC1779 used in various indications34–38. This evidence concerns the gene VWF and Arterial thrombosis.